Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01950364 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma (NCT01950364)

Trial Description
This is an open-label trial to estimate the concentrations of MMAE in relapsed/refractory Hodgkin Lymphoma (HL) or relapsed/refractory Systemic Anaplastic Large Cell Lymphoma (sALCL) patients treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.

This trial is sponsored by Millennium Pharmaceuticals. [1]

Study Data

Study Schematic

Screen Shot 2016-07-18 at 3.15.44 PM

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar